10 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 2, 6 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Terminated 2, Active not recruiting 1 |
| Phase 3 | 6 | Completed 3, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
Follow Myocet: new trials by email Literature Review of Myocet trials Research Report on Myocet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mural Oncology, Inc | 456 | 2022-01-10 | 2025-08-28 |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Blinatumomab, Bortezomib, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric | Phase 3 | Recruiting | Martin Schrappe | 5000 | 2018-07-15 | 2025-04-06 |
| Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer Carboplatin, Paclitaxel, Doxorubicin - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Completed | University of Wisconsin, Madison | 29 | 2017-11-07 | 2026-02-13 |
| A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Brentuximab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Active not recruiting | Patrick Reagan | 24 | 2016-06-01 | 2025-08-12 |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel - Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III | Phase 3 | Completed | GBG Forschungs GmbH | 961 | 2014-12-01 | 2017-07-13 |
| A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response Myocet, Cyclophosphamide, Paclitaxel - Early Primary Breast Cancer | Phase 3 | Completed | Women's Cancer Study Group GmbH | 80 | 2014-07-01 | 2025-02-27 |
| Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb RCOMP, RCHOP - Lymphoma | Phase 2 | Completed | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 91 | 2013-10-11 | 2024-02-26 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Carboplatin, background treatment - Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 595 | 2011-08-01 | 2016-02-15 |
| Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma Doxorubicin - Malignant Glioma | Phase 1 | Completed | Central Hospital, Nancy, France | 13 | 2010-10-01 | 2016-08-10 |
| Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients Metformin + Myocet + Cyclophosphamide, Myocet + Cyclophosphamide - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Completed | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 126 | 2010-09-01 | 2016-01-01 |
| Myocet Plus Endoxan for Older Patients With Breast Cancer Cyclophosphamide, Liposomal-encapsulated doxorubicin - Breast Cancer | Phase 2 | Terminated | Hellenic Oncology Research Group | 64 | 2009-09-01 | 2015-10-07 |
| Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma Rituximab, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 94 | 2007-12-01 | 2013-08-30 |
| Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin liposomal Doxorubicin, Myocet / Paclitaxel - Metastatic Breast Cancer | Phase 2 | Terminated | Claudia Lorenz-Schlüter | 26 | 2006-12-01 | 2014-09-03 |
| Trial of Myocet in Metastatic Breast Cancer Myocet - Breast Cancer | Phase 3 | Unknown | Sopherion Therapeutics | 363 | 2006-01-01 | 2009-03-31 |
| Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients Myocet, Taxotere, Herceptin - Breast Cancer | Phase 1 / Phase 2 | Completed | Spanish Breast Cancer Research Group | 73 | 2004-01-01 | 2023-03-06 |
| A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer trastuzumab, paclitaxel, Myocet - Breast Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 69 | 2001-07-01 | 2015-03-12 |
Breast Neoplasms (8) · Carcinoma, Ductal, Breast (2) · Inflammatory Breast Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Cardiotoxicity (1) · Fallopian Tube Neoplasms (1) · Glioma (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Ovarian Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Triple Negative Breast Neoplasms (1)
GBG Forschungs GmbH (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Central Hospital, Nancy, France (1) · Claudia Lorenz-Schlüter (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · Hellenic Oncology Research Group (1) · Hoffmann-La Roche (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Martin Schrappe (1) · Mural Oncology, Inc (1) · Patrick Reagan (1) · Sopherion Therapeutics (1) · Spanish Breast Cancer Research Group (1) · University of Wisconsin, Madison (1) · Women's Cancer Study Group GmbH (1)
Germany (7) · Spain (5) · Italy (4) · United States (4) · Austria (3) · Australia (2) · Canada (2) · Czechia (2) · France (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Greece (1) · India (1) · Israel (1)
Andreas Schneeweiss, MD, Prof. (1) · Dimitris Mavrudis, MD (1) · Dino Amadori, MD (1) · Dr. Alejandro Martin (1) · Dr. Francisco Gual (1) · Dr. Juan Manuel Sancho (1) · Gunter von Minckwitz, MD, Prof (1) · Joachim Bischoff, Dr. med. (1) · Jose Baselga, M.D. (1) · Kari Wisinski, MD (1) · Martin Schrappe, MD (1) · Michael A Fridrik, MD (1) · Nadia Harbeck, Prof. Dr. (1)
PMID 15148277, PMID 15226333, PMID 17654614, PMID 19074216, PMID 20007997, PMID 20603435, PMID 20728699, PMID 21892906, PMID 24401928, PMID 24794243, PMID 25199759, PMID 25534375, PMID 28715532, PMID 30528802, PMID 32163106, PMID 32200486, PMID 33191846, PMID 33492774, PMID 34252375, PMID 34801353, PMID 35129146, PMID 37334673, PMID 38841802, PMID 41671463, PMID 42748428
2009 (2)